TNF and rheumatoid arthritis: Most notably, in RA, TNF inhibitors have been shown to be protective for cardiovascular events (CVE) and Major Adverse Cardiovascular Events (MACE),26 whereas similar outcomes have been hypothesized for PsA based on data derived from psoriasis studies.26–28 The aspects above need to be considered when assessing the safety profile of JAKi, while the risk for Herpes Zoster Virus (HZV) reactivation merits special attention.